Rhythm Pharmaceuticals Inc (RYTM NASDAQ) stock market data APIs
$98.1047
2.67(2.7%)
as of November 10, 2025
Try our APIs with
free plan!
Rhythm Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Prev. Close
98.1047
Open
100.7762
High
101.2015
Low
96.948
52 wk Range
45.905-116
Market Cap
6 694 M
Shares Outstanding
66 736 K
Revenue
174 M
EPS
-0.82
Beta
1.96
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Rhythm Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rhythm Pharmaceuticals Inc data using free add-ons & libraries
Get Rhythm Pharmaceuticals Inc Fundamental Data
Rhythm Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 174 M
- EBITDA: -184 759 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-11
- EPS/Forecast: -0.6874
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rhythm Pharmaceuticals Inc News
New
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
Rhythm Pharmaceuticals, Inc. – Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP...
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
Key Points Rythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options. Shulman still held 8,509 shares directly after the trade.These 10 stocks co...
Sector Update: Health Care Stocks Retreat Friday Afternoon
Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
It's been a sad week for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), who've watched their investment drop 12% to US$98.49 in the week since the company reported its third-quarter result. The statutory...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
